Patient confidentiality is a major reason why minors do not seek out prevention, testing, and treatment services for sexually transmitted infections (STIs) and HIV.
In a research letter published in JAMA, authors assessed existing minor consent laws surrounding sexually transmitted infection (STI) and HIV services in the United States, comparing confidentiality protection measures across the 50 states and the District of Columbia.
A significant reason why some adolescents do not seek out these services is confidentiality, including concern that a parent or guardian will find out, especially if the child is on their health insurance plan.
To address this barrier and encourage STI/HIV testing, treatment, and prevention, states have enacted statutes granting minors legal capacity to consent to these services without the involvement of their parent or guardian.
“Although reviews of STI/HIV minor consent laws exist, many are dated, have unclear methodology, provide conflicting information, or lack details needed to serve adolescents, researchers, and clinicians,” the authors of the letter wrote.
In this assessment, laws were divided into consent to:
Most states defined age of minority as younger than 18, with Alabama and Nebraska defining it as younger than 19, and Mississippi and Pennsylvania defining it as younger than 21.
As of 2021, in all 51 jurisdictions across the states and the District of Columbia, minors can independently consent to STI/HIV testing and treatment.
Most states allow all minors to consent to STI (n = 43) and HIV (n = 42) testing and treatment without a minimum age. In the remaining states, minors can consent to STI/HIV testing and treatment starting between ages 12 and 14 years, depending on the state.
For prevention, minors can consent to STI prevention services in 33 states, and HIV prevention services in 35 states. Additionally, 14 states established criteria individuals must meet in order to consent independently.
The following conditions must be met to some degree for minors to be legally able to consent to care in these 14 states:
Approximately half of states have the following disclosure rules for clinicians:
Additionally, surgical or nonsurgical care must be deemed “essential to the health or life of such child in the opinion of the performing physician and a consultant physician if one is available” in some states.
“Trainings, policies, and procedures that support and routinize the application of these statutes may empower clinicians to rely on them more confidently in practice,” the authors said. “Ensuring that clinicians, researchers, and minors understand and trust these minor consent laws may expand access to STI/HIV services for youth.”
Reference
Nelson KM, Skinner A, Underhill K. Minor consent laws for sexually transmitted infection and HIV services. JAMA. 2022;328(7):674-676. doi:10.1001/jama.2022.10777
Research Shows Prior Authorization Denials Delay Critical Immunology Care
May 10th 2024Results featured at the Academy of Managed Care Pharmacy 2024 annual meeting revealed a pattern of prior authorization rejections that could delay necessary therapeutic treatments for various patient groups.
Read More
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
Looking Back on ISPOR 2024: Hot Policy Topics, Welcome Focus on Employers, and More
May 10th 2024Kimberly Westrich, MA, chief strategy officer of the National Pharmaceutical Council, reflects on the most valuable learnings from the 2024 meeting of ISPOR—The Professional Society for Health Economics and Outcomes Research, including lively discussions of the Inflation Reduction Act and workshops on value assessment.
Read More
CMS Medicare Final Rule: Advancing Benefits, Competition, and Consumer Protection
May 7th 2024On this episode of Managed Care Cast, we're talking with Karen Iapoce, senior director of government products and programs at ZeOmega, about the recent CMS final rule on Medicare Part D and Medicare Advantage.
Listen
Patients With Advanced, Recurrent Melanoma May Experience Lasting AEs From ICM Therapy
May 9th 2024A cross-sectional, mixed-methods study found that adverse effects (AEs) can occur even after 1 year of treatment with immune checkpoint modulator (ICM) therapy in patients with melanoma.
Read More